The experimental anti-CD30 antibody-drug conjugate (brentuximab vedotin) has given promising results in HIV-negative ALCL [18] but, to our knowledge, has not been tested in HIV patients. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.